Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
RCT (n=716) reports significantly greater proportions of patients in the guselkumab every 4 weeks group (64%) and every 8 weeks group (64%) achieved ACR20 at 24 weeks vs placebo (33%) [percentage differences vs placebo 31% for both; both p<0.0001).
Source:
The Lancet
SPS commentary:
A separate publication describes the outcomes for guselkumab use in patients who had previously received TNFα inhibitor treatment (DISCOVER-1).
In a related editorial, authors highlight that the major limiting factor influencing the interpretation of the results of both studies is the typical selective population investigated, without the frequent multimorbidity profile of patients that are typically seen clinically with psoriatic arthritis.